loading
Clearmind Medicine Inc stock is traded at $0.889, with a volume of 56,822. It is up +0.84% in the last 24 hours and down -8.35% over the past month. Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$0.8816
Open:
$0.9
24h Volume:
56,822
Relative Volume:
0.24
Market Cap:
$4.60M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.0208
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
+0.28%
1M Performance:
-8.35%
6M Performance:
-40.73%
1Y Performance:
-33.66%
1-Day Range:
Value
$0.8512
$0.90
1-Week Range:
Value
$0.8301
$0.9328
52-Week Range:
Value
$0.80
$2.30

Clearmind Medicine Inc Stock (CMND) Company Profile

Name
Name
Clearmind Medicine Inc
Name
Phone
-
Name
Address
-
Name
Employee
1
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
CMND's Discussions on Twitter

Compare CMND with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CMND
Clearmind Medicine Inc
0.889 4.60M 0 -6.78M -4.67M -42.70
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Clearmind Medicine Inc Stock (CMND) Latest News

pulisher
Jun 16, 2025

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com

Jun 16, 2025
pulisher
Jun 16, 2025

Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update - Defense World

Jun 16, 2025
pulisher
Jun 13, 2025

Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants - Psychedelic Alpha

Jun 13, 2025
pulisher
Jun 12, 2025

Clearmind Medicine Inc. (NASDAQ:CMND) Shares Acquired by Citadel Advisors LLC - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

# Clearmind Medicine hires lobbying firm to advance psychedelic therapy By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

# Clearmind Medicine hires lobbying firm to advance psychedelic therapy - Investing.com Australia

Jun 12, 2025
pulisher
Jun 12, 2025

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics - The Manila Times

Jun 12, 2025
pulisher
Jun 12, 2025

Clearmind Medicine Partners with Leading Government Affairs Firm to Advance Psychedelic Therapeutics - Nasdaq

Jun 12, 2025
pulisher
Jun 12, 2025

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic ... - Bluefield Daily Telegraph

Jun 12, 2025
pulisher
Jun 05, 2025

Clearmind Medicine Announces Enrollment Of First Patient In Phase I/Iia Clinical Trial For Alcohol Use Disorder Treatment - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment - The Manila Times

Jun 05, 2025
pulisher
Jun 05, 2025

Clearmind Medicine Inc. Begins Phase I/IIa Trial for CMND-100 to Treat Alcohol Use Disorder - Nasdaq

Jun 05, 2025
pulisher
May 30, 2025

symbol__ Stock Quote Price and Forecast - CNN

May 30, 2025
pulisher
May 20, 2025

Longeveron® to Attend BIO International Convention 2025 - TradingView

May 20, 2025
pulisher
May 12, 2025

SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire

May 12, 2025
pulisher
May 12, 2025

SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc. - Nasdaq

May 12, 2025
pulisher
May 12, 2025

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times

May 12, 2025
pulisher
May 12, 2025

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times

May 12, 2025
pulisher
May 05, 2025

Stocks Under $1 To Watch: $NITO, $SPRC, $PNPNF, $NCNA, $PRSO – Multi-Sectors Momentum Building more inside… | FinancialContent - FinancialContent

May 05, 2025
pulisher
Apr 28, 2025

Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.

Apr 28, 2025
pulisher
Apr 25, 2025

Clearmind Medicine files patent for eating disorder treatment - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

SciSparc and Clearmind file patent for eating disorder treatment - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

Clearmind Medicine files patent for eating disorder treatment By Investing.com - Investing.com South Africa

Apr 25, 2025
pulisher
Apr 25, 2025

SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India

Apr 25, 2025
pulisher
Apr 25, 2025

Psychedelic: Clearmind completes clinical site initiations for AUD trial - Yahoo Finance

Apr 25, 2025
pulisher
Apr 25, 2025

SciSparc and Clearmind File Patent for Eating Disorder Treatment - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - The Manila Times

Apr 25, 2025
pulisher
Apr 25, 2025

SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire

Apr 25, 2025
pulisher
Apr 25, 2025

Clearmind Medicine Inc. Files International Patent for Novel Treatment of Eating Disorders Using 3-MMC and PEA - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan

Apr 25, 2025
pulisher
Apr 23, 2025

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Clearmind Medicine Inc. Initiates Patient Enrollment for Phase I/IIa Clinical Trial in Alcohol Use Disorder - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Clearmind Medicine (NASDAQ:CMND) Stock Price Down 4.8% – Here’s Why - Defense World

Apr 23, 2025
pulisher
Apr 22, 2025

Clearmind Medicine Inc (CMND) requires closer examination - uspostnews.com

Apr 22, 2025
pulisher
Apr 21, 2025

Clearmind Medicine Inc Inc. (CMND) Price Performance and Its Relation to the Tech Industry - investchronicle.com

Apr 21, 2025
pulisher
Apr 21, 2025

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - TradingView

Apr 21, 2025
pulisher
Apr 21, 2025

Clearmind Medicine to Host Live Webinar 'Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - The Manila Times

Apr 21, 2025
pulisher
Apr 21, 2025

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading - Bluefield Daily Telegraph

Apr 21, 2025
pulisher
Apr 17, 2025

Clearmind Medicine Receives Notice Of Allowance For United States Patent Covering Binge Behavior - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior - TradingView

Apr 17, 2025
pulisher
Apr 16, 2025

Clearmind Medicine Launches First U.S. Clinical Site For FDA-Approved Alcohol Use Disorder Trial - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

Clearmind Medicine begins phase I/IIa trial for AUD treatment - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism - The Manila Times

Apr 16, 2025
pulisher
Apr 16, 2025

Clearmind Medicine Inc. Initiates Phase I/IIa Clinical Trial for CMND-100 in Alcohol Use Disorder at Johns Hopkins University - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

Clearmind Medicine Launches First U.S. Clinical Site For Its FDA-Approved Clinical Trial To Combat Alcoholism - MarketScreener

Apr 16, 2025
pulisher
Apr 11, 2025

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial - Yahoo Finance

Apr 11, 2025
pulisher
Apr 11, 2025

Clearmind Medicine (CMND) Launches U.S. Clinical Trial for Alcoh - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder - The Manila Times

Apr 10, 2025
pulisher
Apr 08, 2025

Clearmind Medicine files patent for new psychedelic compounds - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders - The Manila Times

Apr 08, 2025
pulisher
Apr 07, 2025

Clearmind Medicine stock hits 52-week low at $0.95 By Investing.com - Investing.com South Africa

Apr 07, 2025

Clearmind Medicine Inc Stock (CMND) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Cap:     |  Volume (24h):